JIAYUN LIU
Wellesley,MA
Summary
- Accomplished scientist with 20 years expertise in molecular biology, biochemistry and gene therapy research.
- Successfully developed cell lines to produce FVIII and AAV
- Comprehensive expertise in vector genome engineering for designing and producing both viral and non-viral vectors.
Overview
17
17
years of professional experience
Work History
Senior Principal Scientist
Frontera Therapeutics
01.2023 - 03.2024
- Researched on diseases targeting modalities with viral and non-viral vectors to express circular RNA/ tRNA and miRNA in various cell lines
- Conducted AAV genome engineering to make more episomal stable, and less integrated AAV vectors by adding novel S/MAR sequence and mammalian replicators
- Produced low immunogenic circular RNA in vitro using group I and group II intron self splicing strategy
- Developed a HEK based reporter cell line and assays to monitor durability of various constructs.
Principal Scientist
Frontera Therapeutics
02.2022 - 12.2022
- Supervised junior scientists to produce AAV vectors at various scales from cell culture to down stream processing
- Improved AAV yields by optimizing baculovirus/sf9 transfection and banking process
- Designed genetic regulatory circuits to achieve controllable transgene expression and to minimize the genotoxicity
Senior Scientist II
Novartis, Preclinical Safety Department
12.2019 - 02.2022
- Investigated the safety profile of ZOLGENSMA and found the mRNA accumulation issue in nucleus via RNA scope
- Investigated double stranded RNA caused innate immunity and developed a Toll-like receptor 9 over expression/reporter cell line
- Investigated pivotal host factors that affect AAV's replication and transcription
- Supervised junior scientists to produce AAV vectors in house.
Senior Research Scientist
Bioverativ and Sanof, Hemophilia/Gene Therapy Section
02.2017 - 12.2019
- Cloned the first human synthesized B19 virus ITR and develop it as a non viral gene therapy platform
- Increased titers of lenti vectors expressing FVIII 8-10 folds by screening medium nutrients
- Helped Genewiz develop their current protocol for ITR sequencing.
Research Scientist
Biogenidec,Hemophilia Department
06.2013 - 02.2017
- Screened and "elegantly" engineered coagulant FVIII constructs BIVV001/Altuviiio) to achieve extended half-life and enabled its IND filing
- Produced large scale of ALPROLIX Coagulation Factor IX Recombinant), Fc Fusion Protein] expression in house and did comprehensive characterization work to support clinical trial
- Developed stable producer lines (CHO and HEK based) for recombinant proteins production.
Senior Research Associate/ Postdoc Fellow
Kaelin Lab, Dana-Farber Cancer Institute, Harvard Medical School
07.2007 - 10.2013
- Worked on prolyl hydroxylase and oxygen sensing pathway in the lab of Nobel Laureate Dr.William Kaelin with genome wide shRNA screening
- Developed a high throughput platform for in vitro transcription/translation to screen novel hydroxylase.
Education
M. S in Biotechnology -
The State University of New York at Buffalo
12.2006
MD -
Hunan College of Chinese Medicine
07.1995
Skills
- Molecular Cloning
- Cell line development
- plasmids production
- Western/Southern blotting
- Produce circular RNA in vitro and in vivo
- Viral vector design and engineering
- AAV & lenti Delivery
Accomplishments
- Elegantly"engineered BIVV001 - Altuviiio,rFVIIIFcVWF-XTEN and enabled its IND filing
- Cloned and patented the first human synthesized B19 virus ITR, which laid out foundation of the current non-viral gene therapy program at Sanofi
- Deep understanding of AAV biology and RNA biology; Successfully used AAV vectors to express circular RNA/ tRNA and achieved extended expression of transgenes
Selected Publications
- MiR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and FoxO1., J Exp Clin Cancer Res, 2023 May 2, Yu L, Sui B, Zhang X, Liu J, Hao X, Zheng L, 10.1186/s13046-023-02685-2
- Tumor-derived extracellular vesicle nucleic acids as promising diagnostic biomarkers for prostate cancer., Front Oncol, 2023 Jun 29, Diao Y, Zhu B, Ding T, Li R, Li J, Yang L, Zhou L, Hao X, Liu J., 10.3389/fonc.2023.1201554
- BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice., Blood, 2020 Apr 23, Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R., 10.1182/blood.2019001292
- Nucleic acid molecules and uses thereof, Patent WO2019032898A1, Alexey SEREGIN, Tongyao Liu, Susannah PATARROYO-WHITE, Douglas DRAGER, Robert T. Peters, Jiayun LIU, https://patents.google.com/patent/WO2019032898A1/en
- MicroRNA-184 inhibits cell proliferation and metastasis in human colorectal cancer by directly targeting IGF-1R., Oncol Lett, 2017 Sep, Wu G, Liu J, Wu Z, Wu X, Yao X.
- A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo., Cancer Biol Ther, 2016 May 3, Diao Y, Liu J, Ma Y, Su M, Zhang H, Hao X
- Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase., Genes Dev, 2014 Jul 1, Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, Gygi SP, Kaelin WG Jr, Zhang Q.
- Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1., Proc Natl Acad Sci U S A, 2011 Aug 16, Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, Minamishima YA, Zhang Q, Kulkarni RN, Signoretti S, Rodig SJ, Bronson RT, Orkin SH, Tuck DP, Benevolenskaya EV, Meyerson M, Kaelin WG Jr, Yan Q, 10.1073/pnas.1110104108
- Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase., Cancer cell, 2009 Nov 6, Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, Boehm JS, Ni M, Geisen C, Root DE, Polyak K, Brown M, Richardson AL, Hahn WC, Kaelin WG Jr, Bommi-Reddy A.
- Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity., Acta Biochim Biophys Sinica, 2009 Mar, Shen J, Liu J, Long Y, Miao Y, Su M, Zhang Q, Han H, Hao X., 10.1093/abbs/gmp005
Timeline
Senior Principal Scientist
Frontera Therapeutics
01.2023 - 03.2024
Principal Scientist
Frontera Therapeutics
02.2022 - 12.2022
Senior Scientist II
Novartis, Preclinical Safety Department
12.2019 - 02.2022
Senior Research Scientist
Bioverativ and Sanof, Hemophilia/Gene Therapy Section
02.2017 - 12.2019
Research Scientist
Biogenidec,Hemophilia Department
06.2013 - 02.2017
Senior Research Associate/ Postdoc Fellow
Kaelin Lab, Dana-Farber Cancer Institute, Harvard Medical School
07.2007 - 10.2013
M. S in Biotechnology -
The State University of New York at Buffalo
MD -
Hunan College of Chinese Medicine